[An electromyographic study on the development of optimal tactics of botulinum toxin type A injections in children with spastic forms of cerebral palsy]

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(5 Pt 2):53-60.
[Article in Russian]

Abstract

We studied 67 children, aged 2-9 years, with cerebral palsy including 56 children with a spastic form. An electromyographic method was used for the development of optimal tactics of botulinum toxin type A injections in different clinical presentations of spasticity. The best clinical results were obtained in children with the following changes on EMG: 1) the tonic muscle activity in resting state was minimal (<10 microvolts) and had local or regional distribution; 2) the pathological synkinetic activity during voluntary movements was minimal (synergetic activity coefficient for shin muscles was less than 0.45); 3) the disturbance of interactions between synergistic and antagonistic muscles was moderate (reciprocity coefficient was not less than 0.4); 4) EMG amplitude in voluntary muscle contraction should not be less than 150 microvolts. This approach to the treatment allowed to reach higher levels on The Gross Motor Function Classification System in part of children.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Botulinum Toxins, Type A / administration & dosage*
  • Cerebral Palsy / complications
  • Cerebral Palsy / drug therapy*
  • Cerebral Palsy / physiopathology
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Electromyography / methods*
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Intramuscular
  • Leg / physiopathology
  • Male
  • Muscle Contraction / drug effects*
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / etiology
  • Muscle Spasticity / physiopathology
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / physiopathology*
  • Neuromuscular Agents / administration & dosage
  • Practice Guidelines as Topic / standards*
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A